SCHEMBL21296472

SCHEMBL21296472

CCOC(=O)c1c([N+](=O)[O-])cnn1COCC[Si](C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 4/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 1/20 0.38
USP10 Q14694 1/20 0.38
GSTP1 P09211 1/20 0.37
GSTM2 P28161 1/20 0.37
HPGD P15428 2/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
RAB9A P51151 2/20 0.36
PTGER4 P35408 1/20 0.36
LMNA P02545 1/20 0.36
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296485 0.90 GAA (0.40) ALDH1A1SMN1; SMN2KDM4EHPGDKMT2A
SCHEMBL30079470 0.86 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL4021391 0.86 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2POLBHPGDKMT2A
SCHEMBL18131162 0.82 MAPT (0.43) ALDH1A1SMN1; SMN2MAPTPOLBKDM4E
SCHEMBL7513902 0.81 SMN1; SMN2 (0.58) ALDH1A1SMN1; SMN2MAPTPOLBKDM4E
SCHEMBL15726275 0.81 DGAT1 (0.38) ALDH1A1SMN1; SMN2LMNANPC1
SCHEMBL11890433 0.80 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MAPTPOLBKMT2A
SCHEMBL20642921 0.80 DGAT1 (0.37) ALDH1A1SMN1; SMN2MAPTKDM4EHPGD
SCHEMBL30730255 0.80 UCHL1 (0.40) ALDH1A1MAPTLMNANPC1
SCHEMBL7455786 0.79 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3755699-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2020-12-30 EP disclosed
US-20200392161-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF SCHRÖDINGER, INC. 2020-12-17 US disclosed
WO-2019165073-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392161-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPRCAP, PTPRJ, PTPRC ALDH1A1 3858/4885SMN1; SMN2 2591/4885MAPT 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.